Do utilization management controls for phototherapy increase the prescription of biologics?

Gregory L. Simpson, Christopher B. Yelverton, Sheila Rittenberg, Steven R. Feldman

Research output: Contribution to journalReview articlepeer-review

16 Citations (Scopus)

Abstract

The use of phototherapy for psoriasis has declined because of inconvenience, managed care disincentives, and poor reimbursements. However, phototherapy is safer than other options, and the efficacy rates for different methods of phototherapy are among the highest of all available treatment options. Phototherapy is also one of the least costly treatments for moderate-to-severe psoriasis. We hypothesize that utilization management controls on phototherapy shift patients to more expensive and risky systemic treatments. Reducing disincentives on phototherapy will benefit both patients and payors, while increasing physicians' ability to manage this debilitating disease.

Original languageEnglish
Pages (from-to)359-361
Number of pages3
JournalJournal of Dermatological Treatment
Volume17
Issue number6
DOIs
Publication statusPublished - Dec 2006
Externally publishedYes

Keywords

  • Biological therapy
  • Cost control
  • Psoriasis therapy

ASJC Scopus subject areas

  • Dermatology

Fingerprint

Dive into the research topics of 'Do utilization management controls for phototherapy increase the prescription of biologics?'. Together they form a unique fingerprint.

Cite this